Member Info for Wigwammer

Every holder here now experiencing what wildbunch, GG and myself had to put up with in 2024. Lordlollywally’s stagnant and vacuous interventions. In the end the shares multiplied and lolly got it horribly wrong, but as you can see, he is incapable of humility and self reflection… GLA IMO DYOR

Yes. Rog changes his mind 3 times a week but he still thinks the world NEEDS to know his view… Have had him on filter for ages and pleased other people are dealing with his sh-te.. GLA

Will be away from the screen for much of the day again, but good luck IMMers! Remember several of the sceptics here were doing the same thing in 2024 - and the shares consequently multiplied. The people who can’t sort fact from speculation is them! GLA IMO DYOR

What are you on about, nolupus? I can’t make it any clearer. The FDA consider p140 to be a late stage asset, in contradiction to what you stated yesterday. That is why they are willing to endorse late stage trial protocols for p140… GLA IMO DYOR

Well I’m off for the day. Good luck IMMers. Don’t let those perennial sceptics twist things to their agenda .. LOL :)

Sticking to facts then, nolupus. I didn’t call you any names. And contrary to your earlier point, the FDA consider p140 to be a late stage asset. That is why they are willing to endorse late stage trial protocols for p140. A drug does not have to be on the market or near approval, to be considered an asset. DYOR IMO GLA

Actually nolupus, I have simply invested my money well, locked in a profit, and recorded much of my activity here (unlike you). Your description of this as “p&d” just makes you sound bitter, presumably because much of your former scepticism now appears poorly judged… And I will repeat what i said. The FDA consider p140 to be a late stage asset. That is why they are willing to endorse late stage trial protocols for p140. A drug does not have to be on the market or near approval, to be considered an asset. DYOR IMO GLA

Ah nolupus.. another poster who has been disagreeing with me for the last two years. For the record - disagreeing with nolupus can be highly lucrative : I currently have millions of free shares in IMM having locked in my original investment plus a six figure profit on top… Re FDA from AI : “ New Phase 2/3 Trial Protocol: Based on the FDA's guidance, ImmuPharma and Avion designed a substantially different Phase 2/3 adaptive clinical trial protocol. The new design includes higher subcutaneous dosing and changes to patient inclusion criteria and endpoints.

FDA Endorsement: The FDA provided comprehensive guidance and endorsed the proposed protocol for the new Phase 2/3 adaptive clinical trial for lupus.” IMO DYOR GLA

But nobody is buying shares in Tim. Tim’s role is largely to keep the company afloat. Job done. What you are buying here is the potential of a pharmaceutical asset - p140 - please see research by CNRS, engagement with FDA, feedback from IMM science team, Jackson Labs etc etc … IMO DYOR GLA

Again, xviolet, very selective use of facts. Thank you for conceding that the FDA recognises p140 as a late stage asset. Humira was also a late stage asset with a failed trial behind it, and we know what happened there. The key is in trial design. New diagnostics, better understanding of moa, higher dose etc. All good reasons to believe a result could be different this time. Also thank you for conceding that there is large and growing interest in the autoimmune space, that multiple CDA’s have been signed, that HLK have processed a new patent application with potential to add 20 years patent life, shall we add that company is funded for the foreseeable?! Etc … I recall you being uncertain at 2p as well. IMO DYOR GLA

Lollywally was saying the same things at sub 2p. But he neither bought at 2p. Nor sold at 18p. Just a pointless commentator with no conviction about the endless carp he dumps here.. imo dyor gla

But rather selective facts, xviolet..

Jackson labs have verified the data.

HLK have processed the patent application.

Multiple companies have signed CDA’s

Many $bn deals have been signed in the autoimmune space in recent years.

The FDA do regard p140 as a late stage asset.

The market cap is tiny for a company with late stage assets in blockbuster indications etc etc

DYOR IMO GLA

Tim uses the term “access fee”. From AI : “ In pharmaceutical deals, an access fee generally refers to an upfront payment made by one party to another to secure the rights or ability to use a specific technology, product, or market.”

With respect volmer, the shares have multiplied this year to better reflect the underlying value, and the company is now funded well into q426. Not a bad outcome really. IMO DYOR GLA

Ah. I see scroddy. So you’ve held on to all your shares because you have superior conviction Tim will get a deal done, but now you say you don’t have enormous conviction he will get a deal done. Oh well, you make no sense at all, but moaning about Tim will always get a few ticks. GLA

Yes scroddy. You must have enormous faith that Tim is going to gel a deal done. Which makes all your chat about the importance of trust and how little you trust Tim all the more vacuous. GLA IMO DYOR

LOL. So scroddy has made decent capital gains here and he really believes it is all ill-gotten, but he’s going to keep his profits anyway :).. Surprise surprise… And he will continue to hold his IMM shares because he trusts Tim enough to get a deal done (despite all the vitriol he keeps spitting..) A man of true conviction … GLA IMO DYOR

That’s sweet scroddy. So will you be setting up a fund and donating your capital gains to compensate those you claim lost out? .. You continue to hold the shares regardless of your stated views, which I suspect means you don’t really believe what you’re saying (you just like being all bolshy with people). IMO

Yes here you are, scroddy cat, owning the shares .. :)

There weren’t many people who trusted that IMM could get funding this time last year. Now 11 months on, management have delivered funding through to end of 2026 - at marginal dilution - providing a good cash runway to complete a deal. This has also in part been enabled by rigorous cost control. Yes they missed a target, but a fair assessment requires a more balanced reflection. IMO DYOR GLA